AKT3 Gene Editing


Our promise to you:
Guaranteed product quality, expert customer support.


AKT3 Gene Editing    

AKT3 (RAC-gamma serine/threonine-protein kinase) is a member of the AKT subfamily of serine/threonine protein kinases, which regulates many processes, including metabolism, proliferation, cell survival, growth, and angiogenesis, through a series of downstream substrates are mediated by serine and/or threonine phosphorylation. Structurally, AKT3 has two specific sites, one in the kinase domain (Thr-305) and the other in the C-terminal regulatory region (Ser-472), which requires phosphorylation to be fully activated (by similarity). IGF-1 induces AKT3 activation and plays a role in regulating cell survival.

AKT3 is the least studied AKT subtype. It plays an important role in brain development and is essential for the survival of malignant glioma cells. The AKT3 subtype may also be a key molecule for up-regulation and down-regulation of MMP13 by IL13. In addition, AKT3 is a key regulator of various tumors such as melanoma, glioma and ovarian cancer. Active AKT3 gradually increases in the development of melanoma tumors and is the highest in advanced metastatic melanoma. Promoting melanoma by reducing apoptosis plays a key role in the development of ovarian cancer by regulating the G2/M phase transition.

Given the strong homology of the primary amino acid sequence, it has long been speculated that these three AKT kinases act as redundant and overlapping. Recent studies have pointed out the specific functions of AKT isoforms in different cellular events and diseases. AKT1 is more specifically involved in cell survival pathways by inhibiting the apoptotic process. AKT2 is more specific for the insulin receptor signaling pathway. Furthermore, although AKT1 and AKT2 typically involve many aspects of cell transformation, the two subtypes function in complementary opposite ways. The role of AKT3 is unclear, although it appears to be primarily expressed in the brain.

AKT3 Gene Editing Service

CRISPR/Cas9 PlatformCB provides you with comprehensive CRISPR/Cas9 gene editing services and products to a wide range of genomics researchers. With deep gene editing knowledge and extensive experience in experimental operation and data processing, we can help you effectively control target genes editing (including deletion, insertion or point mutation, etc.) in vivo and in vitro using the CRISPR/Cas9 system.

  • AKT3 Gene Editing Cell Line Generation

Our scientists have successfully implemented AKT3 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. To support your projects, we offer you full-length custom AKT3 gene editing service from strategy design to final stable cells.

Our AKT3 gene editing cell line generation services include

➢ Strategy design
➢ gRNA design and synthesis, donor DNA design and synthesis (if needed)
➢ CRISPR/Cas9 vector construction
➢ Transfection into the cell lines you're interested
➢ Select the high expression cells and sort monoclonal cell
➢ Validate the right edited monoclonal cells by PCR and sequencing
➢ Delivery the stable cells and a final report

Cell lines we offered

➢ Blood Lineage Cells (RAW264.7, HMC1.2, K562, U937 etc.)
➢ Cancer Cell Lines (HEK293, HEK293T, Hela, MCF7, Neuro2a, HepG2, U87, etc.)
➢ Stem Cells (iPSC)
➢ Other Cell Lines (NIH3T3, MCF10, HEME, SW10 etc.)

  • AKT3 Gene Editing Animal Model Generation

CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR/Cas9 technology into animal models, which have been fully recognized by our clients. Tell us your needs, we provide you one-stop-shop AKT3 CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price.

Our AKT3 gene editing animal model generation services include:

➢ AKT3 gene conventional knockout animals
➢ AKT3 gene conditional knockout animals
➢ AKT3 point mutation animals
➢ AKT3 knockin animals

Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

CRISPR/Cas9 PlatformCB is one of the world's leading biotechnology companies with outstanding quality management and quality assurance capabilities, providing the best genetic editing services and products for academic research, biotechnology research, and drug discovery. We are able to adapt the solution to your detailed requirements. We guarantee to provide our customers with high-quality services from early strategic design to the final model. If you have any questions, please feel free to contact us.

Related Products at CRISPR/Cas9 PlatformCB



  1. Nakatani K. et al. Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. Biochem Biophys Res Commun. 1999; 257 (3):906–10.
  2. Tschopp O. et al. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development. 2005; 132:2943–54.
  3. Chen WS. et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001; 15:2203–8.
  4. Burgering BMT & Kops GJP. Cell cycle and death control- long live Forkheads. Trends Biochem Sci. 2002; 27:352–60.
  5. Mure, H. et al. Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro Oncol. 2010; 12, 221-232.
For research use only. Not intended for any clinical use.


Verification code